Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
186
resultados
Última actualización
12/12/2025 [07:58:00]
Resultados 175 a 186 de 186
Resumen de: EP4564005A1
The present invention refers to an in vitro method for diagnosing or screening a chronic inflammatory disease selected from the group comprising: Inflammatory bowel disease (IBD), arthritis or psoriasis.
Resumen de: CN120085016A
The invention relates to the field of biological detection, and particularly provides application of APOA1 as a biomarker in preparation of a product for monitoring the activity of colitis. The invention discloses that the exosome APOA1 is positively correlated with the UC activity for the first time, the plasma exosome of a UC patient has good consistency with the in-situ expression level of the colon, and the severity of the colitis can be known in time on the premise of not making a colonoscope by detecting the expression condition of the APOA1 of the plasma exosome of the patient in vitro. Wide application prospects are realized.
Resumen de: CN120077274A
Provided herein is a method for inspecting irAE enteritis, comprising a detection step for detecting an antibody that immunologically reacts with a fragment or all of integrin alpha v beta 6 in a sample as an indicator of ulcerative colitis-like irAE enteritis.
Resumen de: WO2025109034A1
The present invention relates to a method of determining or predicting the sensitivity of a subject to an anti-inflammatory treatment against IBD using vedolizumab, comprising the steps of: Providing a biological sample of a subject suffering from IBD, determining the methylation status of at least one CpG selected from the group consisting of cg08081727, cg17830959, cg03455316, cg05197062, cg00441209, cg00706914, cg12906381, cg25299227, cg05338672, cg17764313, cg16467921, cg04674762, cg02601475, cg14115807, cg21070860, cg04546413, cg12667521, cg05062694, cg02229781, cg17096289, cg08017465, cg18319102, cg09659072, cg03161606, cg25267487, and determining the sensitivity based on said methylation status wherein a higher level of methylation of cg17830959, cg03455316, cg25299227, cg05197062, cg12906381, cg05338672, cg02601475, cg00706914, cg04674762, cg02229781, cg09659072, cg08017465, cg18319102, cg21070860, cg14115807, and a lower level of methylation of cg08081727, cg00441209, cg17764313, cg16467921, cg05062694, cg25267487, cg03161606, cg04546413, cg17096289, cg12667521 in comparison to a control value or control sample is indicative of an increased sensitivity to a therapy using vedolizumab.
Resumen de: CN120072156A
The invention discloses an ulcerative colitis severity assessment method and system, and relates to the technical field of artificial intelligence, and the method comprises the following steps: data collection and ulcerative colitis symptom classification; preliminarily evaluating the severity of ulcerative colitis according to clinical data; performing correlation analysis based on the preliminary evaluation model and the severity score; performing intelligent diagnosis according to the combination of the severity score and the real-time physiological monitoring data; personalized treatment scheme recommendation is carried out according to the intelligent diagnosis result; evaluating the recovery progress of the patient by using the personalized treatment scheme; performing subsequent illness state prediction according to the recovery progress data; and a long-term monitoring scheme is provided for future disease course management based on a disease prediction result. According to the method, an improved regression analysis method is provided, and a nonlinear term, an interaction effect and a dynamic adjustment mechanism are introduced, so that the model can better capture a nonlinear complex relationship in clinical data, and the prediction precision is remarkably improved.
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: WO2025109148A1
The invention relates to methods for diagnosing inflammatory bowel disease (IBD) and for distinguishing between common gastrointestinal disease (principally functional bowel disease/irritable bowel syndrome and coeliac disease) and IBD, especially in children and in subjects with normal levels of C-reactive protein. The methods are based on measuring the methylation level of at least one CpG site in at least one gene.
Resumen de: CN120072056A
The invention provides application of intestinal flora as a marker in preparation of a product for evaluating the treatment effect of inflammatory bowel diseases. The feasibility of predicting the curative effect of the medicine for treating the inflammatory bowel disease patient by using the microbial spectrum can accurately discriminate the patient needing to optimize the treatment scheme in the early stage of the disease, so that the prognosis condition of the patient is remarkably improved. Meanwhile, the invention provides a construction method of an intestinal flora biomarker prediction model, accurate prediction of the ineffective condition of drug treatment is realized through the combination of faecobacteria prausnitzii, Blauratia massiensis and coma faecalis, and the potential of the intestinal flora biomarker prediction model as a new tool for early recognition of a patient possibly needing optimized treatment is highlighted.
Resumen de: CN120041371A
The invention relates to the technical field of cell biology, in particular to a construction method and application of intestinal organs for children with Crohn's disease, the intestinal organs for children with Crohn's disease are successfully constructed by utilizing intestinal tissues from children with Crohn's disease, and the intestinal organs have various characteristic cells of the intestinal tissues; besides, immune cells are extracted from peripheral blood of a child patient homologous with intestinal tissues, a co-culture system is established with the organ-like model, the intestinal immune microenvironment of the child patient suffering from the Crohn's disease can be reproduced, and the system provides a new model for related mechanism exploration and drug screening of the child Crohn's disease.
Resumen de: CN120047411A
The invention provides a method for assisting in identifying ulcerative colitis inflammatory activity levels based on dynamic graph multi-instance learning. The method comprises the steps of data acquisition, data preprocessing, dynamic graph multi-instance learning model construction of inflammatory activity level diagnosis and model evaluation. The data acquisition mainly comprises the steps of collecting pathological images of a patient with ulcerative colitis, digitalizing the pathological images through a digital scanner, excluding a part of pathological images containing problems such as blurring, fading and abnormal staining, and finally determining a grading label of each pathological image by a deep gastrointestinal pathology expert. The data preprocessing mainly comprises the steps of processing a digital pathological image, converting the digital pathological image into image blocks, then extracting features from each image block by using a visual basic model, and finally constructing a dynamic graph multi-instance learning model for training. According to the method, exploration of the internal relation of the image blocks input to the WSI is promoted, and the prediction effect of the model is improved.
Nº publicación: JP2025081517A 27/05/2025
Solicitante:
中山康方生物医▲藥▼有限公司
Resumen de: PH12022550223A1
Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.
BOPI
Sede Electrónica
